Publications

    Filter by Year:2022 2020 2019 2018 2017 
    27-May-2022
    Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.

    Read More here.

    27-Apr-2022
    Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors

    Read More here.

    8-Apr-2022
    The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.